In a small (n=9) phase I open-label clinical trial, a 3-day oral course of dasatinib plus quercetin reduced senescent-cell markers in adipose tissue and skin of people with diabetic kidney disease.
Notes on verification
Corrected 2026-09-06 verification pass: original wording 'eliminated senescent cells' overstated the actual Hickson et al. 2019 finding, which was a decrease in senescent-cell markers (adipose p16-INK4A -35 percent, p21-CIP1 -17 percent, SA-beta-gal -62 percent) 11 days after a 3-day D+Q course in n=9 patients with diabetic kidney disease. Primary source reassigned from unrelated WebMD aging article (source_id=174) to Hickson 2019 EBioMedicine paper (source_id=3217). Corroborated by AlzForum (source_id=3145) and PMC mirror (source_id=3216). [tier=gold indep_score=0.900 clusters=3 claim_tier=notable reviewed_by=verification_pass_2026_09_06]
Sources
- Is There a Cure for Aging? (seed:health_and_medicine)
- https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30591-2/fulltext (corroboration)
- https://www.alzforum.org/therapeutics/dasatinib-quercetin (corroboration)
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796530/ (corroboration)